https://go.evvnt.com/1003520-0?pid=5248 Hyatt Regency Boston
1 Avenue de Lafayette
Boston, Massachusetts 02111
Lectures & Conferences
The momentum in anti-HER2 drug development is exploding:
Outcomes for HER2-expressing breast cancer are patients constantly improving; diagnostics, trial design and innovative drug design are at an all-time high; complementing the newly accessible HER2 'low' space and wider range of tumor indications; the last year has given us more progress in HER2-targeted therapies than ever before.
As such, the HER2-Targeted Therapies Summit returns for its second year as the only industry-dedicated forum for large pharma, biotech and academia to unite under one roof to discuss these developments, gain competitive insights and ultimately turbocharge practice-changing anti-HER2 drugs to patients.
As the clinical and commercial opportunity of HER2-targeted therapies becomes apparent, join us to connect with over 80+ HER2 experts and expand the clinical utility of your pipeline by exploring HER2 as a multi-tumor target.
Early bird rates are available!
Industry Pricing - Conference + Workshop Day - Standard Rate: USD 4097.0,
Industry Pricing - Conference Only - Standard Rate: USD 2899.0
Speakers: Cecile Geuijen Chief Scientific Officer and Vice President - Oncology, Merus, Shane Olwill Chief Development Officer, Senior Vice President and Head of Translational Science, Pieris Pharmaceuticals, Athanasios Tsiatis Senior Vice President - Clinical Development, ALX Oncology, Edith Perez Chief Medical Officer, Bolt Biotherapeutics, Fredrik Frejd Chief Scientific Officer, Affibody, Roger Waltzman Chief Medical Officer, Molecular Templates, Debora Barton Chief Medical Officer, Carisma Therapeutics, Reva Basho Assistant Professor, Breast Medical Oncology, Co-Director: Women's Cancer Research Program, Cedars-Sinai Medical Center, Gail Lewis Phillips Principal Scientist, Discovery Oncology, Genentech, John Strickler Associate Professor of Medicine, Duke Clinical Research Institute, Deyaa Adib Chief Medical Officer, Triumvira Immunologics, Wendy Hauck Global Associate Medical Director, Women's Cancer Care, Eisai, Funda Meric - Bernstam Chair, Department of Investigational Cancer Therapeutics and Medical Director Institute for Personalized Cancer Therapy, MD Anderson Cancer Center, Fiore Cattaruzza Senior Director - Pharmacology and Preclinical Development Biomarkers, Amunix Pharmaceuticals, RJ Tesi Chief Executive and Medical Officer, Inmune Bio, Aparna Parikh Assistant Professor and Director, Harvard Medical School and MGH Cancer Center's Global Cancer Care Program, Roxana Schillaci Principal Researcher, Institute of Biology and Experimental Medicine CONICET, Argentina, Kirk Tanner Chief Scientific Officer, National Brain Tumor Society, Jenny Karlsson Head of TRP Biochemistry, Bayer, Teemu Junttila Senior Principal Scientist - Technology and Translational Oncology, Genentech, Serena Masciari Senior Medical Director, Oncology Early Development, Sanofi Genzyme, Paul Rennert President and Chief Scientific Officer, Aleta Biotherapeutics, Nataliya Uboha Medical Oncologist, University of Wisconsin School of Medicine and Public Health